Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010139 | 0.89 | FOLH1 (0.46) | MMENAALAD2L3MBTL1FOLH1 | |
| SCHEMBL9809609 | 0.83 | MME (0.51) | MMENPSR1FPR2NAALAD2MMP2 | |
| SCHEMBL9809605 | 0.83 | MME (0.51) | MMENPSR1FPR2NAALAD2MMP2 | |
| SCHEMBL27813467 | 0.80 | MME (0.49) | MMENPSR1FPR2NAALAD2MMP2 | |
| SCHEMBL7211707 | 0.80 | MME (0.51) | MMENPSR1FPR2NAALAD2MMP2 | |
| SCHEMBL6130478 | 0.80 | MME (0.51) | MMENPSR1FPR2NAALAD2MMP2 | |
| SCHEMBL6130477 | 0.80 | MME (0.51) | MMENPSR1FPR2NAALAD2MMP2 | |
| SCHEMBL6009834 | 0.79 | TGFBR1 (0.40) | MMEALDH1A1 | |
| SCHEMBL5017006 | 0.78 | FPR2 (0.51) | MMENPSR1FPR2NAALAD2MMP2 | |
| SCHEMBL14263459 | 0.78 | MME (0.50) | MMENPSR1FPR2NAALAD2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105288634-A | Preparation method of glycerin-amino acid deep eutectic solvent | UNIV NANJING AGRICULTURAL | 2016-02-03 | — | — | CN | disclosed |
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | MME 2180/4885NPSR1 1513/4885FPR2 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.